Switching antiplatelet regimens: Alternatives to clopidogrel in patients with acute coronary syndrome undergoing PCI: A review of the literature and practical considerations for the interventional cardiologist

Catheterization and Cardiovascular Interventions

Volumn 81, Issue 2, 2013, Pages 232-242

  Azmoon, Shahdad ^a   Angiolillo, Dominick J ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

antiplatelet therapy; clopidogrel; PCI; prasugrel; ticagrelor

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; ATORVASTATIN; CANGRELOR; CLOPIDOGREL; ELINOGREL; OMEPRAZOLE; PLACEBO; PRASUGREL; TICAGRELOR; TICLOPIDINE;

ACUTE CORONARY SYNDROME; BLEEDING; CORONARY ARTERY DISEASE; CORONARY STENT; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; HIGH RISK PATIENT; HUMAN; LOADING DRUG DOSE; PATIENT COMPLIANCE; PERCUTANEOUS CORONARY INTERVENTION; PHARMACODYNAMICS; REVIEW; RISK REDUCTION; STENT THROMBOSIS; THROMBOCYTE AGGREGATION;

ACUTE CORONARY SYNDROME; ADENOSINE; ASPIRIN; CORONARY THROMBOSIS; DRUG INTERACTIONS; DRUG SUBSTITUTION; DRUG THERAPY, COMBINATION; HUMANS; PERCUTANEOUS CORONARY INTERVENTION; PHARMACOGENETICS; PIPERAZINES; PLATELET AGGREGATION INHIBITORS; PRACTICE GUIDELINES AS TOPIC; PURINERGIC P2Y RECEPTOR ANTAGONISTS; THIOPHENES; TICLOPIDINE; TIME FACTORS; TREATMENT OUTCOME;

EID: 84874469184     PISSN: 15221946     EISSN: 1522726X     Source Type: Journal    
DOI: 10.1002/ccd.24480     Document Type: Review

References (39)

1. Angiolillo DJ, Ueno M, Goto S,. Basic principles of platelet biology and clinical implications. Circulation 2010; 74: 597-607.
2. Levine GN, Bates ER, Blankenship JC, Bailey SR, Bittl JA, Cercek B, Chambers CE, Ellis SG, Guyton RA, Hollenberg SM, Khot UN, Lange RA, Mauri L, Mehran R, Moussa ID, Mukherjee D, Nallamothu BK, Ting HH, Jacobs AK, Anderson JL, Albert N, Creager MA, Ettinger SM, Halperin JL, Hochman JS, Kushner FG, Ohman EM, Stevenson W, Yancy CW,. 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. Circulation 2011; 124: e574-e651.
3. Bertrand ME, Rupprecht HJ, Urban P, Gershlick AH,. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: The clopidogrel aspirin stent international cooperative study (CLASSICS). Circulation 2000; 102: 624-629.
4. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK,. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345: 494-502.
5. Steinhubl SR, Berger PB, Mann JT III, Fry ET, DeLago A, Wilmer C, Topol EJ,. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: A randomized controlled trial. JAMA 2002; 288: 2411-2420.
6. Angiolillo DJ, Ferreiro JL,. Platelet adenosine diphosphate P2Y12 receptor antagonism: Benefits and limitations of current treatment strategies and future directions. Rev Esp Cardiol 2010; 63: 60-76.
7. Ho PM, Peterson ED, Wang L, Magid DJ, Fihn SD, Larsen GC, Jesse RA, Rumsfeld JS,. Incidence of death and acute myocardial infarction associated with stopping clopidogrel after acute coronary syndrome. JAMA 2008; 299: 532-539.
8. Campo G, Valgimigli M, Gemmati D, Percoco G, Catozzi L, Frangione A, Federici F, Ferrari F, Tebaldi M, Luccarelli S, Parrinello G, Ferrari R,. Poor responsiveness to clopidogrel: Drug-specific or class-effect mechanism? Evidence from a clopidogrel-to-ticlopidine crossover study. J Am Coll Cardiol 2007; 50: 1132-1137.
9. Tomasello SD, Tello-Montoliu A, Angiolillo DJ,. Prasugrel for the treatment of coronary thrombosis: A review of pharmacological properties, indications for use and future development. Expert Opin Invest Drugs 2011; 20: 119-133.
10. Brandt JT, Payne CD, Wiviott SD, Weerakkody G, Farid NA, Small DS, Jakubowski JA, Naganuma H, Winters KJ,. A comparison of prasugrel and clopidogrel loading doses on platelet function: Magnitude of platelet inhibition is related to active metabolite formation. Am Heart J 2007; 153: 66.e9-66.e16.
11. Jernberg T, Payne CD, Winters KJ, Darstein C, Brandt JT, Jakubowski JA, Naganuma H, Siegbahn A, Wallentin L,. Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease. Eur Heart J 2006; 27: 1166-1173.
12. Angiolillo DJ, Badimon JJ, Saucedo JF, Frelinger AL, Michelson AD, Jakubowski JA, Zhu B, Ojeh CK, Baker BA, Effron MB,. A pharmacodynamic comparison of prasugrel vs. high-dose clopidogrel in patients with type 2 diabetes mellitus and coronary artery disease: Results of the Optimizing anti-Platelet Therapy In diabetes MellitUS (OPTIMUS)-3 Trial. Eur Heart J 2011; 32: 838-846.
13. Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, Neumann FJ, Ardissino D, De Servi S, Murphy SA, Riesmeyer J, Weerakkody G, Gibson CM, Antman EM,; TRITON-TIMI Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357: 2001-2015.
14. Wiviott SD, Braunwald E, McCabe CH, Horvath I, Keltai M, Herrman JP, Van de Werf F, Downey WE, Scirica BM, Murphy SA, Antman EM,. Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: A subanalysis of a randomised trial. Lancet 2008; 371: 1353-1363.
15. Murphy SA, Antman EM, Wiviott SD, Weerakkody G, Morocutti G, Huber K, Lopez-Sendon J, McCabe CH, Braunwald E,. Reduction in recurrent cardiovascular events with prasugrel compared with clopidogrel in patients with acute coronary syndromes from the TRITON-TIMI 38 trial. Eur Heart J 2008; 29: 2473-2479.
16. Angiolillo DJ, Saucedo JF, Deraad R, Frelinger AL, Gurbel PA, Costigan TM, Jakubowski JA, Ojeh CK, Effron MB,. Increased platelet inhibition after switching from maintenance clopidogrel to prasugrel in patients with acute coronary syndromes: Results of the SWAP (SWitching Anti Platelet) study. J Am Coll Cardiol 2010; 56: 1017-1023.
17. Wiviott SD, Trenk D, Frelinger AL, O'Donoghue M, Neumann FJ, Michelson AD, Angiolillo DJ, Hod H, Montalescot G, Miller DL, Jakubowski JA, Cairns R, Murphy SA, McCabe CH, Antman EM, Braunwald E,; PRINCIPLE-TIMI Investigators. Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: The Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial. Circulation 2007; 116: 2923-2932.
18. Payne CD, Li YG, Brandt JT, Jakubowski JA, Small DS, Farid NA, Salazar DE, Winters KJ,. Switching directly to prasugrel from clopidogrel results in greater inhibition of platelet aggregation in aspirin-treated subjects. Platelets 2008; 19: 275-281.
19. Jakubowski JA, Payne CD, Li YG, Brandt JT, Small DS, Farid NA, Salazar DE, Winters KJ,. The use of the VerifyNow P2Y12 point-of-care device to monitor platelet function across a range of P2Y12 inhibition levels following prasugrel and clopidogrel administration. Thromb Haemost 2008; 99: 409-415.
20. Montalescot G, Sideris G, Cohen R, Meuleman C, Bal dit Sollier C, Barthelemy O, Henry P, Lim P, Beygui F, Collet JP, Marshall D, Luo J, Petitjean H, Drouet L,. Prasugrel compared with high-dose clopidogrel in acute coronary syndrome. The randomised, double-blind ACAPULCO study. Thromb Haemost 2010; 103: 213-223.
21. Saucedo JF, Angiolillo DJ, DeRaad AL,. Decrease in poor responders in switching from clopidogrel to prasugrel: Results from the SWitching Anti Platelet (SWAP) study. Paper presented at the Annual Meeting of the American Heart Association, Orlando, FL, November 14-18, 2009.
22. Capodanno D, Dharmashankar K, Angiolillo DJ,. Mechanism of action and clinical development of ticagrelor, a novel platelet ADP P2Y12 receptor antagonist. Expert Rev Cardiovasc Ther 2010; 8: 151-158.
23. Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horrow J, Husted S, James S, Katus H, Mahaffey KW, Scirica BM, Skene A, Steg PG, Storey RF, Harrington RA, Freij A, Thorsen M,. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361: 1045-1057.
24. Cannon CP, Harrington RA, James S, Ardissino D, Becker RC, Emanuelsson H, Husted S, Katus H, Keltai M, Khurmi NS, Kontny F, Lewis BS, Steg PG, Storey RF, Wojdyla D, Wallentin L,. Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): A randomised double-blind study. Lancet 2010; 375: 283-293.
25. Gurbel PA, Bliden KP, Butler K, Antonino MJ, Wei C, Teng R, Rasmussen L, Storey RF, Nielsen T, Eikelboom JW, Sabe-Affaki G, Husted S, Kereiakes DJ, Henderson D, Patel DV, Tantry US,. Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: The RESPOND study. Circulation 2010; 121: 1188-1199.
26. Ueno M, Ferreiro JL, Angiolillo DJ,. Update on the clinical development of cangrelor. Expert Rev Cardiovasc Ther 2010; 8: 1069-1077.
27. Dovlatova NL, Jakubowski JA, Sugidachi A, Heptinstall S,. The reversible P2Y antagonist cangrelor influences the ability of the active metabolites of clopidogrel and prasugrel to produce irreversible inhibition of platelet function. J Thromb Haemost 2008; 6: 1153-1159.
28. Steinhubl SR, Oh JJ, Oestreich JH, Ferraris S, Charnigo R, Akers WS,. Transitioning patients from cangrelor to clopidogrel: Pharmacodynamic evidence of a competitive effect. Thromb Res 2008; 121: 527-534.
29. Harrington RA, Stone GW, McNulty S, White HD, Lincoff AM, Gibson CM, Pollack CV Jr, Montalescot G, Mahaffey KW, Kleiman NS, Goodman SG, Amine M, Angiolillo DJ, Becker RC, Chew DP, French WJ, Leisch F, Parikh KH, Skerjanec S, Bhatt DL,. Platelet inhibition with cangrelor in patients undergoing PCI. N Engl J Med 2009; 361: 2318-2329.
30. Bhatt DL, Lincoff AM, Gibson CM, Stone GW, McNulty S, Montalescot G, Kleiman NS, Goodman SG, White HD, Mahaffey KW, Pollack CV Jr, Manoukian SV, Widimsky P, Chew DP, Cura F, Manukov I, Tousek F, Jafar MZ, Arneja J, Skerjanec S, Harrington RA,. Intravenous platelet blockade with cangrelor during PCI. N Engl J Med 2009; 361: 2330-2341.
31. Angiolillo DJ, Schneider DJ, Bhatt DL, French WJ, Price MJ, Saucedo JF, Shaburishvili T, Huber K, Prats J, Liu LS, Harrington RA, Becker RC,. Pharmacodynamic effects of cangrelor and clopidogrel: The Platelet Function Substudy from the Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition in Patients Undergoing Percutaneous Coronary Intervention (CHAMPION-PCI) Trial [Abstract 13354]. Circulation 2011; 124: A13354.
32. Angiolillo DJ, Firstenberg MS, Price MJ, Pradyumma E, Tummala PE, Hutyra M, Welsby IJ, Voeltz MD, Chandna H, Ramaiah C, Brtko M, Cannon L, Dyke C, Liu T, Montalescot G, Manoukian SV, Prats J, Topol EJ,; for the BRIDGE Investigators. Bridging antiplatelet therapy with the intravenous agent cangrelor in patients undergoing cardiac surgery: A randomized controlled trial. JAMA 2012; 307: 265-274.
33. Ueno M, Rao SV, Angiolillo DJ,. Elinogrel: Pharmacological principles, preclinical and early phase clinical testing. Future Cardiol 2010; 6: 445-453.
34. Leonardi S, Rao SV, Harrington RA, Bhatt DL, Gibson CM, Roe MT, Kochman J, Huber K, Zeymer U, Madan M, Gretler DD, McClure MW, Paynter GE, Thompson V, Welsh RC,. Rationale and design of the randomized, double-blind trial testing INtraveNous and Oral administration of elinogrel, a selective and reversible P2Y(12)-receptor inhibitor, versus clopidogrel to eVAluate Tolerability and Efficacy in nonurgent Percutaneous Coronary Interventions patients (INNOVATE-PCI). Am Heart J 2010; 160: 65-72.
35. Angiolillo DJ, Rao SV, Trenk D, Neumann FJ, Conley P, Stephens G, Kochman J, Gurbel PA, Harrington RA, Welsh RC,. Pharmacodynamic substudy from the intravenous and oral administration of elinogrel to evaluate tolerability and efficacy in non-urgent PCI patients (INNOVATE-PCI) trial [abstract P2437]. Presented at the European Society of Cardiology, Paris, France, August 27-31, 2011.
36. Bates ER, Lau WC, Angiolillo DJ,. Clopidogrel-drug interactions. J Am Coll Cardiol 2011; 57: 1251-1263.
37. Mahaffey KW, Wojdyla DM, Carroll K, Becker RC, Storey RF, Angiolillo DJ, Held C, Cannon CP, James S, Pieper KS, Horrow J, Harrington RA, Wallentin L,. Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation 2011; 124: 544-554.
38. Mega JL, Simon T, Collet JP, Anderson JL, Antman EM, Bliden K, Cannon CP, Danchin N, Giusti B, Gurbel P, Horne BD, Hulot JS, Kastrati A, Montalescot G, Neumann FJ, Shen L, Sibbing D, Steg PG, Trenk D, Wiviott SD, Sabatine MS,. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: A meta-analysis. JAMA 2010; 304: 1821-1830.
39. Angiolillo DJ, Ueno M,. Optimizing platelet inhibition in clopidogrel poor metabolizers: Therapeutic options and practical considerations. JACC Cardiovasc Interv 2011; 4: 411-414.